Anteris Technologies Global (NASDAQ:AVR – Get Free Report) and Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.
Valuation & Earnings
This table compares Anteris Technologies Global and Kestra Medical Technologies”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anteris Technologies Global | $1.91 million | 279.56 | -$94.14 million | ($1.61) | -3.40 |
| Kestra Medical Technologies | $106.73 million | 15.80 | -$131.61 million | ($2.67) | -10.60 |
Anteris Technologies Global has higher earnings, but lower revenue than Kestra Medical Technologies. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than Anteris Technologies Global, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Anteris Technologies Global and Kestra Medical Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anteris Technologies Global | -4,637.48% | -57.15% | -50.73% |
| Kestra Medical Technologies | -140.43% | -63.83% | -44.76% |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Anteris Technologies Global and Kestra Medical Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anteris Technologies Global | 1 | 1 | 3 | 0 | 2.40 |
| Kestra Medical Technologies | 1 | 2 | 5 | 0 | 2.50 |
Anteris Technologies Global presently has a consensus target price of $13.75, indicating a potential upside of 151.05%. Kestra Medical Technologies has a consensus target price of $29.00, indicating a potential upside of 2.46%. Given Anteris Technologies Global’s higher possible upside, research analysts clearly believe Anteris Technologies Global is more favorable than Kestra Medical Technologies.
Risk & Volatility
Anteris Technologies Global has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, Kestra Medical Technologies has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500.
Summary
Anteris Technologies Global beats Kestra Medical Technologies on 7 of the 12 factors compared between the two stocks.
About Anteris Technologies Global
Anteris Technologies Global is a medical technology company focused on developing treatments for structural heart disease, particularly aortic valve conditions. Its work centers on transcatheter heart valve technology, which is designed to replace a damaged valve through a minimally invasive procedure. The company’s lead product is the DurAVR transcatheter heart valve. It is made using Anteris’ ADAPT tissue technology, which processes bovine pericardial tissue for use in medical devices. The valve is designed to resemble the structure and function of a healthy aortic valve.
About Kestra Medical Technologies
Kestra Medical Technologies is a medical technology company focused on wearable solutions for people at risk of sudden cardiac arrest. Its products combine cardiac monitoring, treatment technology and digital services intended to support patients and their care teams. The company’s flagship product, the ASSURE wearable cardioverter defibrillator, continuously monitors a patient’s heart rhythm and can deliver a treatment shock if it detects a life-threatening arrhythmia. The system also provides alerts and supports remote sharing of patient data with clinicians.
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
